title: Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study.
abstract: OBJECTIVE
  To compare the effectiveness of doxycycline-rifampin (DR) combination therapy with that of the classic doxycycline-streptomycin (DS) combination in patients with brucellosis.
  
  
  METHODS
  A randomized, double-blind study, with a mean follow-up of 15.7 months.
  
  
  METHODS
  A 1000-bed teaching hospital in Barcelona, Spain.
  
  
  METHODS
  Ninety-five patients (68 men and 27 women; mean age, 39 years) diagnosed with brucellosis on the basis of both clinical and serologic findings; 81 of these patients had blood cultures positive for Brucella melitensis.
  
  
  METHODS
  Forty-four patients received doxycycline, 100 mg every 12 hours, and rifampin, 15 mg/kg body weight per day in a single morning dose, for 45 days; 51 patients received the same dose of doxycycline for 45 days plus streptomycin, 1 g/d for 15 days.
  
  
  METHODS
  Therapeutic failure and relapse during the follow-up period.
  
  
  RESULTS
  The mean time to defervescence was 4.2 days for the DR group and 3.2 days for the DS group (P greater than 0.2). The actuarial probability of therapeutic failure or relapse at 12 months of follow-up (Kaplan-Meier) was 14.4% in the DR group and 5.9% in the DS group (difference, 8.5%; 95% Cl, -4.8% to 21.6%; P greater than 0.2). All three patients with spondylitis in the DR group failed therapy compared with one of four patients in the DS group. Excluding patients with spondylitis, the actuarial failure rate was 4.9% and 4.3% in the DR and DS groups, respectively, at 12 months of follow-up (difference, 0.6%; Cl, -8.1% to 9.4%; P greater than 0.2).
  
  
  CONCLUSIONS
  Doxycycline-rifampin combination therapy for 45 days is as effective as the classic DS combination in most patients with brucellosis; however, DR therapy might be less effective in those patients with spondylitis.
authors.affiliation: Infectious Disease Service, Hospital de Bellvitge, Feixa Llarga, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Ariza
authors.forename: F
authors.initials: F
authors.lastname: Gudiol
authors.forename: R
authors.initials: R
authors.lastname: Pallares
authors.forename: P F
authors.initials: PF
authors.lastname: Viladrich
authors.forename: G
authors.initials: G
authors.lastname: Rufi
authors.forename: J
authors.initials: J
authors.lastname: Corredoira
authors.forename: M R
authors.initials: MR
authors.lastname: Miravitlles
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002006:Brucellosis / Q000188:drug therapy*; D002648:Child; D004311:Double-Blind Method; D004318:Doxycycline / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011336:Probability; D012008:Recurrence; D012293:Rifampin / Q000627:therapeutic use*; D013166:Spondylitis / Q000188:drug therapy / Q000382:microbiology; D013307:Streptomycin / Q000627:therapeutic use*
chemical_list: D004318:Doxycycline; D012293:Rifampin; D013307:Streptomycin